Outcome assessment in acute pancreatitis patients  by Lee, Wei-Sin et al.
Kaohsiung Journal of Medical Sciences (2013) 29, 469e477Available online at www.sciencedirect.com
journal homepage: http: / /www.kjms-onl ine.comORIGINAL ARTICLEOutcome assessment in acute pancreatitis
patientsWei-Sin Lee a, Jee-Fu Huang b,c,*, Wan-Long Chuang a,caDepartment of Internal Medicine, Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan
bDepartment of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung
Medical University, Kaohsiung, Taiwan
c Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University,
Kaohsiung, Taiwan
Received 4 May 2012; accepted 13 July 2012
Available online 12 January 2013KEYWORDS
Acute pancreatitis;
Disease outcome;
Mortality and
morbidity;
Scoring systems;
Systemic
inflammatory
response syndrome* Corresponding author. Department
siung Municipal Hsiao-Kang Hospital, K
482 San-Ming Road, Kaohsiung City 81
E-mail address: jf71218@gmail.com
1607-551X/$36 Copyright ª 2012, Kao
http://dx.doi.org/10.1016/j.kjms.201Abstract Early diagnosis and severity evaluation in patients with acute pancreatitis (AP) are
very important due to its potential morbidity and mortality. Several clinical, laboratory, and
radiologic factors, and many scoring systems have been proposed for outcome prediction.
Although the Ranson and Acute Physiology and Chronic Health Evaluation II scoring systems
have been widely used for decades, the cumbersome components partly limit their predict-
ability. Recently, the Bedside Index for Severity in AP scoring system and series blood urea
nitrogen changes, which are simple and convenient to evaluate within 24 hours after admis-
sion, have been validated for accuracy by several large-cohort studies. The presence of organ
failure and systemic inflammatory response syndrome are also helpful to evaluate the severity
of AP. Herein we review recent advances of the predictive methods for AP to provide an up-to-
date perspective on outcome assessment of AP.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Acute pancreatitis (AP) is a common acute inflammatory
process of the pancreas that usually manifests withof Internal Medicine, Kaoh-
aohsiung Medical University,
2, Taiwan.
(J.-F. Huang).
hsiung Medical University. Publish
2.10.007severe acute upper abdominal pain and elevated
pancreatic enzymes. Overall, 85% of patients have
interstitial pancreatitis, which is usually mild, self-
limiting and has a favorable prognosis. However,
a severe form of AP, necrotizing pancreatitis, develops in
15% (range 4e47%) of AP patients. One-third of these
patients may have infected necrosis and subsequent
complications such as sepsis, multiorgan failure, and
death [1].ed by Elsevier Taiwan LLC. All rights reserved.
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is often variable and difficult to predict. The overall
mortality in AP is approximately 5%, which can be classified
into early and late death. The former is defined as2 weeks
after admission and is attributed to multiorgan failure,
whereas the latter is defined as >2 weeks and is usually
associated with septic complication due to infected necrosis
[1e4]. The prevalence rates of organ failure (OF) in inter-
stitial pancreatitis, infected pancreatitis, and sterile
pancreatitis are 10%, 34e89%, and45e73%, respectively. The
mortality rates in the absence of OF, in the presence of one
OF, and multiorgan failure are 0%, 3%, and 47%, respectively
[5e8]. Different extents of pancreatic necrosis and its
subsequent complications chiefly contribute to the occur-
rence of OF and/or mortality during the admission period
[7,8]. Therefore, the initial assessment of severity in AP to
evaluate OF and the complications of pancreatic necrosis as
soon as possible is critical for the appropriate management
and risk assessment in a clinical setting.Pathophysiological mechanisms
Recent studies showed that AP is generally considered to
have three phases. The first phase is characterized by trypsin
activation within pancreatic acinar cells. Several pathways
provoke trypsin activation, and the most important mecha-
nisms include: (1) cleavage of trypsinogen to trypsin by the
lysosomal hydrolase cathepsin B; (2) trypsin-induced tryp-
sinogen activation (trypsinogen autoactivation); (3) a rise in
intracellular Ca2þ and a disruption of acinar cell Ca2þ
signaling; and (4) decreased activity of the pancreatic
secretory trypsin inhibitor [1,9]. Generally, trypsin activa-
tion is the major hidden player in the scenario.
The second phase involves the activation and chemo-
attraction of leukocytes and macrophages in the pancreas,
resulting in an enhanced intrapancreatic inflammatory
reaction. Neutrophil sequestration can also activate tryp-
sinogen. Neutrophil depletion by administration of anti-
neutrophil serum reduced the extent of necrosis and
inflammatory infiltrate in experimental studies [1,9,10].
In the third phase, there is extrapancreatic inflamma-
tion. Local release of cytokines triggers chemotaxis of
activated granulocytes and macrophages. These immune
cells also release cytokines, such as tumor necrosis factor-
a, interleukin-1, and interleukin-6, activating Kupffer cells
in the liver. The Kupffer cells increase cytokine levels in the
blood, which in turn mediates distant organ damage such as
systemic inflammatory response syndrome (SIRS), acute
respiratory distress syndrome or multiorgan failure [10].Diagnosis
Serologic tests
A diagnosis of AP requires at least two of the following
three features: (1) abdominal pain characteristic of AP; (2)
serum amylase and/or lipase 3 times the upper limit of
normal; and (3) characteristic findings of AP on imaging
studies, particularly computed tomography (CT) scan [1]. In
AP, the serum amylase and lipase are usually elevatedwithin 24 hours of onset and remains so for 3e7 days. Serum
lipase level is more specific and sensitive than serum
amylase level. Both values may be normal in AP, notably
confounded by delayed blood sampling, underlying chronic
pancreatitis, or hypertriglyceridemia. Values 3 times the
upper limit of normal virtually confirm the diagnosis of AP.
Some disorders may also mildly influence serum amylase
level, such as renal insufficiency or salivary gland lesion.
However, the extent of pancreatic enzymes elevation does
not reflect the severity of AP.Imaging modalities
To diagnose AP, there are several noninvasive imaging tests,
including ultrasound (US), CT, and magnetic resonance
imaging (MRI). The choice of a specific imaging modality
should take the following reasons into consideration: (1) the
timingofonsetof symptoms; (2) the severityandcomplication
of pancreatitis; (3) the associated biliary tract abnormalities
such as biliary obstruction, gallstone or choledocholithiasis;
and (4) the potential contraindication of imaging tests.
The identification of biliary gallstones by US is nearly
90%, whereas it may reach 80% in the diagnosis of chol-
edocholithiasis [11]. US is also the most convenient and
easy-to-access tool in a clinical setting. However, accurate
evaluation of the whole pancreatic gland in AP remains
difficult and presents some limitations. The evaluation of
parenchymal perfusion and the border between paren-
chymal necrosis and edema are quite limited on US [11]. A
dynamic ileus may also occur in AP patients, which may
significantly undermine the performance of US evaluation.
Contrast-enhanced abdominal CT is the best imaging
modality regarding the diagnosis of AP due to the following
attributes: (1) it can be performed rapidly and urgently; (2)
it is informative in the evaluation of the severity and the
complication; (3) helps to approach in patients with sus-
pected chronic pancreatitis; (4) other disorders that are
clinically similar to AP can be accurately excluded; and (5)
interference from bowel gas can be largely avoided.
According to the CT severity index (CTSI, or Balth-
azareRanson criteria for severity) [12], CT scanning
provides mortality and morbidity information (Table 1).
Compared to acute physiology and chronic health evalua-
tion II (APACHE II) score, CTSI has the advantages of: (1)
better sensitivity, specificity, and negative and positive
predictive values for severe pancreatitis; (2) prediction of
the morbidity and mortality; and (3) being a good predictor
of local complications [13,14]. Generally, CTSI is conducted
72 hours after admission, whereas the APACHE II scale is
calculated at 24 hours or 48 hours. For predicting systemic
OF and the need of intensive care, APACHE II is more
confident than CTSI. Contrast-enhanced CT is contra-
indicated if there is significant renal impairment or history
of significant allergy to contrast medium. Therefore, non-
contrast CT scanning (if emergent) or MRI may be better
choices to evaluate the severity of AP.
In the evaluation of AP, MRI has some potential advan-
tages: (1) lack of nephrotoxicity of gadolinium as compared
to an iodinated contrast; (2) application in pregnant women
and children for dose-related issues or in patients
with history of contrast allergy; (3) acquisition of
Table 1 The grading of acute pancreatitis and computed tomography (CT) severity index.
CT grading (unenhanced CT score)
Grade Findings Scores
A Normal pancreas 0
B Focal or diffuse enlargement of the pancreas 1
C Peripancreatic inflammation with intrinsic pancreatic
abnormalities
2
D Intrapancreatic or extrapancreatic fluid collections 3
E Two or more large fluid collection or gas in the pancreas
or retroperitoneum
4
Necrosis score based on contrast-enhanced CT
The percentage of necrosis
0 0
<30% 2
30e50% 4
>50% 6
CT grading Mortality (%) Morbidity (%)
Grade AþBþC (No fluid collections) 0 4
Grade DþE (Fluid collections) 14 54
Necrosis
No necrosis 0 6
Necrosis 23 82
CTSI (CT grading þ necrosis)
0e2 0 4
3e6 6 35
7e10 17 92
Table 2 Severe acute pancreatitis as defined by the
Atlanta Symposium.
Item Comment
Early prognostic
signs
1. Ranson criteria 3 points, or
2. APACHE II 8 points
or
Organ failure 1. Shock: systolic blood pressure
<90 mmHg
2. PaO2 60 mmHg
3. Creatinine >20 mg/L after rehydration
4. Gastrointestinal bleeding
>500 mL/24 h
and/or
Local
complication
1. Pancreatic necrosis
2. Abscess
3. Pseudocyst
Acute pancreatitis outcome assessment 471MRCP sequences to evaluate choledocholithiasis-induced
pancreatitis; and (4) greater ability to distinguish necrosis
from fluid [1,11]. A high sensitivity (100%) and specificity
(98%) of MRCP in the diagnosis of choledocholithiasis was
recognized especially for stones >3 mm in diameter [11].
Patients who have early diagnosis of gallstone-induced
pancreatitis can receive urgent endoscopic retrograde
cholangiopancreatography, which leads to a lower rate of
recurrence and complications [15]. MRI can also accurately
determine disease severity and predict clinical outcome
during the course of AP. Several studies showed that MR
severity index, with the same grading evaluation as CTSI,
possesses a performance comparable with CT and Ranson
score [16e18]. MRI is also correlated well with APACHE II
score in terms of mortality, morbidity, duration of hospital-
ization and the need for intensive care [19]. Therefore, MRI is
a better alternative for AP if contrast CT is contraindicated.
Methods and scoring systems for severity
assessment in AP
The initial assessment of severity in AP is critical for the
appropriate triage and management of patients due to its
high mortality and morbidity in severe cases. Criteria of
severe AP, including early prognostic signs, OF, and local
complication, were initially established in 1992 (Table 2) [1].
There are several simple predictors to evaluate the
prognosis on admission or in the emergency department.
Old age, defined as age over 75 years, is a definite predictor
for poorer prognosis [1]. Frey et al. demonstrated that ascompared with patients aged 35 years or under, patients
over 75 years carried a more than 15-fold and 22-fold of
death within 2 weeks and 91 days, respectively [20]. Older
age is also associated with mortality in the first 48 hours of
AP occurrence but it is not related to the development of
persistent or deteriorating multiorgan dysfunction
syndrome [21].
Several studies have found that obesity (body mass
index > 30) is a risk factor for disease progression in AP [1].
In a meta-analysis study with 739 patients, obese patients
developed significantly more severe AP [odds ratio (OR) 2.9,
95% confidence interval (CI) 1.8e4.6], systemic
472 W.-S. Lee et al.complications (OR 2.3, 95% CI 1.4e3.8), local complications
(OR 3.8, 95% CI 2.4e6.6), and showed a higher mortality
(OR 2.1, 95% CI 1.0e4.8) than their counterparts [22].
Patients with android fat distribution (central or visceral
obesity) also had a relative risk of 4.36 or more in devel-
oping severe AP [23]. The combination of APACHE-II and
obesity (APACHE-O) measured within the first 24 hours of
admission improved the prediction of severity (BMI score,
<26: scoreZ 0, 26e30: scoreZ 1 and >30: scoreZ 2). At
a cut-off of >8, APACHE-O had a sensitivity of 82%, a spec-
ificity of 86%, a positive predictive value of 74%, a negative
predictive value of 91% and an overall accuracy of 85% [24].
SIRS is defined by two or more of the following criteria:
(1) pulse >90 beats/min; (2) respiratory rate >20/min or
PCO2 <32 mmHg; (3) rectal temperature <36
C or >38C;
and (4) white blood count <4  109/L or >12  109/L
or > 10% bands. The presence of SIRS on admission, at 24
hours and 48 hours as well as persistent SIRS (defined as
SIRS present for the entire 48 hours) has a significantly
higher mortality rate as compared with the absence of SIRS
in patients with severe AP [25]. Persistent SIRS leads to
a strong risk of persistent or deteriorating multiorgan
dysfunction syndrome development [21]. In addition,
patients with persistent SIRS have higher rate of persistent
OF, pancreatic necrosis, and greater need of intensive care,
compared to those with transient or no SIRS [26].
OF, an advanced and extreme consequence of inflam-
matory processes, is also a good predictor for mortality and
local complication in AP, especially during the 1st week (i.e.
early OF). There is a strong association between persistent
OF (>48 hours) and local complication [4]. Transient OF (<
48 hours) was also associated with a mortality rate of 1.4 %,
in contrast to 35% of persistent OF. Meanwhile, the pres-
ence of early OF has a lower survival rate than the absence
of OF, and persistent as well as deteriorating OF have
a higher mortality rate than transient, resolved OF [25].
The occurrence of OF combined with infected pancreatic
necrosis suggests a grave outcome [27].
Ranson criteria
Ranson criteria have been used since 1974 to evaluate the
severity and mortality of AP (Table 3). Severe AP is defined
when the Ranson score is 3 points. Mortality was 0e3%Table 3 Ranson criteria for severity prediction of acute pancre
0 hour
Age >55 y
White blood cell count >16  109/L
Blood glucose >2.0 mg/L (11.1 mM)
Lactate dehydrogenase (LDH) >350 U/L
Aspartate aminotransferase (AST) >250 U/L
48 hours
Hematocrit decrease by 10%
Blood urea nitrogen increase by 50 mg/L (1.8 mM) despite fluid
Serum calcium <80 mg/L (2 mM)
pO2 <60 mmHg
Base deficit >4 MEq/L
Fluid sequestration >6 Lwhen the score was <3, 11e15% when the score was 3,
and 40% when the score was 6 [1]. Five factors are
assessed at admission and the other six factors are assessed
during the next 48 hours. However, Ranson criteria are
cumbersome, laborious and not clinically practical.
Complete evaluation after 48 hours may miss the golden
time for therapy. A meta-analysis of 110 studies also found
that the Ranson score has very poor positive and negative
predictive value for severe AP [28]. Therefore, there has
been a continuous need for an easy-to-access and useful
method for decades.APACHE scores
The APACHE II score was originally developed for critically
ill patients in intensive care units (Table 4). A higher
APACHE-II score at admission and during the first 72 hours is
correlated with a higher mortality (<4% with an APACHE-
II < 8 and 11e18% with an APACHE-II > 8) [1]. However,
APACHE II score is also complex and more cumbersome than
Ranson criteria. Furthermore, it does not differentiate well
between interstitial and necrotizing pancreatitis and
between sterile and infected necrosis [1]. Therefore, the
clinical role of APACHE II score for AP severity assessment is
declining compared to other predictors such as MR severity
index and SIRS [19,26].Bedside index for severity in AP
The Bedside Index for Severity in AP (BISAP) score is a new
scoring system first described in 2008. Development of the
BISAP score was based upon 17,922 cases of AP from 212
hospitals in 2000e2001 and validated in 18,256 cases from
177 hospitals in 2004e2005 [29]. In this study, several
candidate risk factors were proposed: (1) individual Ranson
criteria; (2) pleural effusion (on chest radiology or CT); (3)
SIRS; (4) OF; (5) altered mental status; and (6) hemoglobin
and hemoconcentration. The worst vital signs and positive
findings of physical examination were also utilized. All risk
factors were analyzed by classification and regression tree
(CART) analysis. However, the serum calcium, lactate
dehydrogenase, PaO2 and aspartate aminotransferaseatitis.
Comment
1. Each item means one point.
2. Severe pancreatitis:
Ranson criteria 3 points
3. Mortality:
0e2 Points: 0e3%
3e5 Points: 11e15%
6e11 Points: 40%
s
Table 4 Acute physiology and chronic health evaluation II (APACHE II) score.
þ4 þ3 þ2 þ1 0 þ1 þ2 þ3 þ4
Rectal temperature
(C)
41 39e40.9 38e38.9 36e38.4 34e35.9 32e33.9 30e31.9 29.9
MAP (mmHg) 160 130e159 110e129 70e109 50e69 49
Heart rate (/min) 180 140e179 110e139 70e109 55e69 40e54 40
Respiratory rate
(/min)
50 35e49 25e34 12e24 10e11 6e9 5
If FiO2 50%, check A-a gradient; if FiO2 <50%, PaO2
A-a gradient 500 350e499 200e349 <200
PaO2 (mmHg) >70 61e70 55e60 <55
Arterial pH 7.7 7.6e7.69 7.5e7.59 7.3e7.49 7.25e7.3 7.15e7.2 <7.15
Na (mM) 180 160e179 155e159 150e154 130e149 120e129 111e19 110
K (mM) 7 6e6.9 5e5.9 3.5e4.9 3e3.4 2.5e2.9 <2.5
Creatinine(mg/L) 35 20e34 15e19 6.0e14 <6.0
Hematocrit (%) 60 50e59.9 46e49.9 30e45.9 20e29.9 <20
WBC count(109/L) 40 20e39.9 15e19.9 3e14.9 1e2.9 <1
Glasgow coma score (GCS): 0e12 points Z 15eGCS
Age (y) Points
<44 0 Chronic health (history of chronic conditions)a Points
45e54 2 None 0
55e64 3 If patient is admitted after elective surgery 2
65e74 5 If patient is admitted after emergency surgery or for
reason other than after elective surgery
5
>75 6
A-a gradient Z alveolar-arterial oxygen difference; K Z serum potassium; MAP Z mean blood pressure; Na Z serum sodium;
WBC Z white blood cell.
a Chronic health conditions: liver, cirrhosis with portal hypertension or encephalopathy; cardiovascular, class IV angina (at rest or with
minimal self-care activities); pulmonary, chronic hypoxemia or hypercapnia, polycythemia, ventilator dependent; kidney, chronic
peritoneal or hemodialysis; immune, immunocompromised host.
Acute pancreatitis outcome assessment 473measurements were excluded due to their failure to meet
the pre-specified 85% collection rate threshold.
The risk points of BISAP score includes blood urea
nitrogen (BUN) > 250 mg/L, impaired mental status, SIRS
(2 criteria), age > 60 years, and pleural effusion within 24
hours after admission. In the derivation cohort after CART
analysis, BUN was identified as the most efficient first
splitting variable. Age and SIRS further discriminated
between high- and low-risk cases. Both the mortality rate
and the area under curve (AUC) were comparable between
the derivation and the validation cohorts and APACHE-II
score were similar (AUC: 0.83, 0.82 and 0.83 of the deri-
vation cohort, validation cohort, and APACHE-II score,
respectively). The BISAP score also had performance char-
acteristics for mortality prediction, which were comparable
with the APACHE II score. However, in this study, the BISAP
score can only be a predictor for in-hospital mortality of AP.
In another prospective study with 397 cases [30], the
trend for increasing mortality with increasing BISAP score
was statistically significant (p < 0.0001, and AUC was 0.82).
Of 397 cases, 230 were admitted with their first episode of
AP, and mortality was also significant (p < 0.0001) with
increasing BISAP score in this subgroup. Patients with
a BISAP score  3 were 7.4, 12.7, and 3.8 times more likely
to develop OF (after 24 hours), persistent OF (>48 hours),
and pancreatic necrosis, respectively.
The BISAP score was compared to Ranson scores,
APACHE II scores, and CTSI scores in another prospectivestudy [31]. The AUCs for BISAP, Ranson, APACHE-II, and CTSI
in predicting severe AP are 0.81, 0.94, 0.78, and 0.84,
respectively. However, the BISAP score has lower sensi-
tivity, but similar or higher specificity than the other three
traditional scoring methods.
In summary, the BISAP score is more reliable than the
traditional scoring systems due to the following advan-
tages: (1) it is easily memorable; (2) it can be used within
24 hours for severe AP exclusion; and (3) two variables (i.e.
BUN and SIRS) can be evaluated continuously for the
development of complications, such as mortality and
persistent OF, at 24 hours and 48 hours. Further studies
should focus on how to increase post-test probability of
severe disease (or pancreatic necrosis or death), making
the BISAP score a powerful predictor in AP.Serial BUN levels and other laboratory tests
In all risk factors, BUN was identified as the most efficient
splitting variable by CART analysis [29]. The relationship
between series BUN levels and AP complications has been
consistently addressed. In a large hospital-based cohort
[32], serial BUN measurements were the most reliable
single routine laboratory test to predict the mortality in AP.
The adjusted odds ratio for mortality was 2.2 for every
increase in the BUN of 50 mg/L during the first 24 hours,
whereas it was 1.0 for every increase in the hemoglobin
474 W.-S. Lee et al.(Hb) of 10 g/dL during the first 24 hours. There was
a significant correlation between the extent of BUN change
and the risk of mortality. Increasing AUC of BUN was also
significantly observed between admission and 24 hours
after admission, but not between 24 hours and 48 hours
after admission. A BUN level of 200 mg/L at admission was
associated with an increased risk of death compared with
a BUN level of <200 mg/L. Any increase in BUN at 24 hours
was also associated with an increased risk of death. More-
over, among patients with an elevated BUN level at
admission (>200 mg/L), a decrease of at least 50 mg/L at
24 hours after admission was associated with reduced risk
of in-hospital death [33].
A higher hematocrit level (hemoconcentration) subse-
quent to fluid loss in the third space is considered asFigure 1. Flowchart for acute pancreata single reliable severity predictor in AP. AP patients with
hematocrit level <44e47% at admission and failure to
recover 24 hours later have a high possibility to develop
necrotizing pancreatitis [34,35]. Hemoconcentration is
also a predictor of OF, and patients with hematocrit
criteria should be admitted urgently to an intensive care
unit for vigorous fluid resuscitation [36]. The absence of
hemoconcentration usually excludes a suspicion of
pancreatic necrosis, and a contrast-enhanced CT may not
be necessary. However, inconsistent results have been
postulated in spite of consistent findings of a high nega-
tive predictive value of hemoconcentration for necrosis
and OF. The absence of hemoconcentration at admission
and during the first 24 hours is generally suggestive of
a benign clinical course. However, hematocrit is notitis diagnosis and severity assessment.
Acute pancreatitis outcome assessment 475a single reliable predictor for OF, mortality, and severity
in AP.
Hypocalcemia, one item of Ranson criteria calculated at
48 hours of AP development, is associated with severity and
necrosis of AP. The precise pathogenesis is incompletelyTable 5 Summary of clinical, laboratory, radiologic risk factors
Item Mortality Severity Pancreatic
necrosis
Persistent
organ
failure
Characteristics of patients
Old age S The ol
Obesity S S Definit
Centra
Single laboratory test
Series BUN S The m
is > 20
at 24 h
Pros: E
Cons:
the AU
Hematocrit S Hemat
Pros: e
Cons:
Calcium S Pros: g
Cons:
Imaging scores
CTSI S S S The on
to Ran
Pros: e
necros
Cons:
contra
MRSI S S S Pros: a
better
predic
Cons:
Other scoring system
SIRS S S S S Can be
condit
d, and
and m
Organ failure S S S Can be
condit
Patien
higher
BISAP S S S S Pros: e
BUN an
APACHE-II S S Pros: g
Cons:
Ranson score S S Pros: h
Cons:
practic
48 h
AP Z acute pancreatitis; APACHE-II Z Acute Physiology and Chron
BISAPZ Bedside Index for Severity of AP; BUNZ blood urea nitrogen;
index; ICU Z intensive care unit; MRSI Z magnetic resonance sev
SIRS Z systemic inflammatory response syndrome.understood. It may be attributed to binding of calcium
during the process of fat necrosis and altered levels of
circulating parathyroid hormone in AP [37,38]. Serum
calcium level as well as plasma interleukin-10 and serum
glucose were identified as independent predictors of OF inand scoring systems for acute pancreatitis.
Comments, Pros and Cons Reference
der age, the higher mortality 20, 21
ion of obesity: body mass index > 30 kg/m2
l or visceral obesity is more significant
22e25
ortality is higher if the initial BUN level
0 mg/L and the following BUN level increases
asy evaluation
only significant in mortality
C of 24 h and 48 h are not different
34, 35
ocrit  44% 36e40
asy to evaluate
cannot evaluate mortality
ood predictor in organ failure 42
cannot evaluate mortality
ly one scoring system is proven to be superior
son criteria and APACHE II
asy to perform accurately diagnose pancreatic
is
contraindicated in patients with allergy to
st, impaired renal function, or pregnancy
12e14, 32,44
lternative if contrast CT is contraindicated
diagnosis for biliary pancreatitis good
tor in length of hospitalization & need for ICU
11, 15e19
cannot be performed rapidly and urgently
evaluated once per day according to clinical
ion Patients with persistent SIRS, SIRS within 1
3 or 4 SIRS criteria have higher complication
ortality
4, 21, 27
evaluated once per day according to clinical
ion
4, 28
ts with persistent or early organ failure have
complication and mortality
arly predictor within 24 h easily accessible
d SIRS can be evaluated continuously
30e33
ood predictor for intensive care
cumbersome and laborious
1, 19 27
as been used and validated for 40 y
cumbersome, laborious and not clinically
al may miss the golden time of therapy after
1, 29
ic Health Examination II; APACHE-O Z APACHE-II and obesity;
CRPZ C-reactive protein; CTSIZ computed tomography severity
erity index; OF Z organ failure; S Z significantly predictable;
476 W.-S. Lee et al.AP [39]. The combination of an elevated interleukin-10
concentration (>50 pg/mL) and a decreasing calcium
concentration (<65 mM or <68 g/L) was a significantly
better predictor than any single marker or APACHE II score,
with a sensitivity of 88% and specificity 93%. Hypocalcemia
has been widely adapted as an important predictor within
72 hours for disease severity [38,40].
Other serum markers have been studied for predicting
the severity of AP including the following: serum c-reactive
protein, urinary trypsinogen activation peptide, procalci-
tonin, polymorphonuclear elastase, pancreatic-associated
protein, procarboxypeptidase-B, carboxypeptidase B acti-
vation peptide, serum trypsinogen-2, phospholipase A-2,
serum amyloid protein-A, substance P, antithrombin III,
platelet activating factor, interleukins-1, 6, 8, and 10,
tumor necrosis factor-a, or soluble tumor necrosis factor
receptor, and various genetic polymorphisms. However,
most serum markers were not widely available in the clin-
ical setting because of their limitations of predictability
and accessibility.
Future perspectives and conclusion
Early diagnosis and evaluation for the severity and
mortality of AP are very important (Fig. 1). Severe AP can
be predicted by using clinical, laboratory, imaging, and/or
many scoring systems (Table 5). In various scoring systems
and laboratory tests, the Ranson and APACHE-II scoring
systems have been used widely for decades. However,
these are cumbersome in intent and may delay treatment
implementation due to limited predictability. BISAP scoring
system and series BUN changes have been validated for
accuracy by several large-cohort studies [29,32]. Mean-
while, both tests are simple and convenient to evaluate
within 24 hours after admission. However, a complemen-
tary application of the assessment methods is essential
because a single method does not reliably predict the
development of morbidity and mortality. For example,
imaging scoring has good evaluation for pancreatic necrosis
but it is a poor predictor for OF. Only SIRS and OF can
evaluate the severity after 48 hours. Therefore, to find
a simple and easy-to-access panel and/or biomarkers over
the whole clinical course is the further research goal.
Further validation among AP patients of different etiolo-
gies, race and regions will be mandatory in order to eluci-
date the diverse outcomes of the disease. For example,
previous study in Taiwan demonstrated that CTSI is superior
to Ranson criteria and APACHE II score [40]. Patients with
CTSI  5 have higher mortality, longer duration of hospi-
talization (20 days), and complications. In addition, host
susceptibility regarding genetic and proteomic studies is
helpful for clarification of the whole pathogenic context of
AP. It will also be informative to assess various outcome
measurement tools based on personalized medicine in the
future.
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